Sarissa goes after Alkermes, seeking three board seats at the Irish drugmaker

Paul Schloesser

Associate Editor

Activist investor Sarissa Capital Management is calling on Alkermes shareholders to vote for three of its proposed board members, saying the current board has limited …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarissa goes after Alkermes, seeking three board seats at the Irish drugmaker

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Saris­sa goes af­ter Alk­er­mes, seek­ing three board seats at the Irish drug­mak­er

Associate Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Sarissa goes after Alkermes, seeking three board seats at the Irish drugmaker